A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen.

A multicenter phase II trial of the triplet antiemetic therapy with palonosetron, aprepitant, and olanzapine for a cisplatin-containing regimen. - PATROL-I-

Published:2023-12-06 Issue: Volume: Page:
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Tsuji Daiki^ORCID,Nakagaki Shigeru,Yonezawa Itsuki,Suzuki Kenichi,Yokokawa Takashi,Kawasaki Yohei,Yamaguchi Takumi,Kawaguchi Takashi,Hatori Masahiro,Matsumoto Takuma,Sakata Yukio,Yamamoto Keisuke,Nishimura Tomoyasu,Kogure Yuki,Hayashi Toshinobu,Osawa Misa,Itoh Kunihiko,Watanabe Masaya

Funder

Japan Society for the Promotion of Science

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

https://link.springer.com/content/pdf/10.1007/s10637-023-01414-y.pdf

Reference32 articles.

1. Fernández-Ortega P, Caloto MT, Chirveches E, Marquilles R, Francisco JS, Quesada A et al (2012) Chemotherapy-induced nausea and vomiting in clinical practice: impact on patients’ quality of life. Support Care Cancer 20:3141–3148. https://doi.org/10.1007/s00520-012-1448-1

2. Burke TA, Wisniewski T, Ernst FR (2011) Resource utilization and costs associated with chemotherapy-induced nausea and vomiting (CINV) following highly or moderately emetogenic chemotherapy administered in the US outpatient hospital setting. Support Care Cancer 19:131–140. https://doi.org/10.1007/s00520-009-0797-x

3. Navari RM, Qin R, Ruddy KJ, Liu H, Powell SF, Bajaj M et al (2016) Olanzapine for the Prevention of Chemotherapy-Induced nausea and vomiting. N Engl J Med 375:134–142. https://doi.org/10.1056/NEJMoa1515725

4. Hashimoto H, Abe M, Tokuyama O, Mizutani H, Uchitomi Y, Yamaguchi T et al (2020) Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy-induced nausea and vomiting (J-FORCE): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21:242–249. https://doi.org/10.1016/S1470-2045(19)30678-3

5. Chow R, Herrstedt J, Aapro M, Chiu L, Lam H, Prsic E et al (2021) Olanzapine for the prophylaxis and rescue of chemotherapy-induced nausea and vomiting: a systematic review, meta-analysis, cumulative meta-analysis and fragility assessment of the literature. Support Care Cancer 29:3439–3459. https://doi.org/10.1007/s00520-020-05935-7